DTIL logo

DTIL
Precision Biosciences Inc

3,727
Mkt Cap
$136M
Volume
67,842.00
52W High
$8.82
52W Low
$3.53
PE Ratio
-1.06
DTIL Fundamentals
Price
$5.70
Prev Close
$5.50
Open
$5.45
50D MA
$4.73
Beta
0.74
Avg. Volume
197,857.01
EPS (Annual)
-$3.63
P/B
1.44
Rev/Employee
$503,882.35
$33.42
Loading...
Loading...
News
all
press releases
Precision BioSciences (DTIL) Expected to Announce Earnings on Tuesday
Precision BioSciences (NASDAQ:DTIL) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-31-precision-biosciences-inc-stock...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
Q1 EPS Estimate for Precision BioSciences Raised by Analyst
Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for Precision BioSciences in a research note issued on Thursday, March 19th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn...
MarketBeat·10d ago
News Placeholder
Brokers Set Expectations for DTIL Q1 Earnings
Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) - Equities researchers at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Precision BioSciences in a research report issued on Thursday, March 19th. HC Wainwright analyst P. Trucchio anticipates that the company will p...
MarketBeat·12d ago
News Placeholder
Precision BioSciences (NASDAQ:DTIL) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen upgraded Precision BioSciences from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·18d ago
News Placeholder
Precision BioSciences (NASDAQ:DTIL) Trading Up 12.1% - Here's Why
Precision BioSciences (NASDAQ:DTIL) Stock Price Up 12.1% - What's Next...
MarketBeat·20d ago
News Placeholder
Precision BioSciences (DTIL) Surpasses Q4 Earnings and Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of +271.43% and +178.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·20d ago
News Placeholder
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire·20d ago
News Placeholder
Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire·21d ago
News Placeholder
Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Business Wire·22d ago
News Placeholder
Coherus Oncology (CHRS) Reports Q4 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -9.68% and -2.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·23d ago
<
1
2
...
>

Latest DTIL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.